Paper · 41616005
Resveratrol inhibits bladder cancer proliferation by targeting the AURKA/STAT3 axis: From computational analysis to experimental validation.
Feng C and 5 others. PLoS One, 2026. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Resveratrol inhibits bladder cancer proliferation by targeting the AURKA/STAT3 axis: From computational analysis to experimental validation. Papers, record 41616005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41616005
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Resveratrol inhibits bladder cancer proliferation by targeting the AURKA/STAT3 axis: From computational analysis to experimental validation.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| STAT3 Transcription Factor | Major topic |
| Aurora Kinase A | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Cell Proliferation | Major topic |
| Resveratrol | Major topic |
| Humans | |
| Cell Line, Tumor | |
| Signal Transduction | |
| Apoptosis | |
| Pyrimidines | |
| Gene Expression Regulation, Neoplastic | |
| Azepines | |
| Computational Biology |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33,749,701 | Resveratrol effects in bladder cancer: A mini review. | Genet Mol Biol | 2021 | https://conductscience.org/library/papers/33749701 | PubMed |
| 2 | 40,276,769 | Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphoma. | iScience | 2025 | https://conductscience.org/library/papers/40276769 | PubMed |
| 3 | 38,713,626 | Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression. | Proc Natl Acad Sci U S A | 2024 | https://conductscience.org/library/papers/38713626 | PubMed |
| 4 | 39,945,337 | Treatment Patterns and Radical Cystectomy Outcomes in Patients Diagnosed With Urothelial Nonmetastatic Muscle-Invasive Bladder Cancer in the United States. | Cancer Med | 2025 | https://conductscience.org/library/papers/39945337 | PubMed |
| 5 | 39,606,239 | Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies. | Front Immunol | 2024 | https://conductscience.org/library/papers/39606239 | PubMed |
| 6 | 33,451,333 | Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy. | Mol Cancer | 2021 | https://conductscience.org/library/papers/33451333 | PubMed |
| 7 | 39,011,676 | Nano-Bacillus Calmette-Guérin immunotherapies for improved bladder cancer treatment. | J Zhejiang Univ Sci B | 2024 | https://conductscience.org/library/papers/39011676 | PubMed |
| 8 | 25,061,499 | Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells. | Genes Cancer | 2014 | https://conductscience.org/library/papers/25061499 | PubMed |
| 9 | 40,159,464 | Dual Targeting of Aurora-A and Bcl-xL Synergistically Reshapes the Immune Microenvironment and Induces Apoptosis in Breast Cancer. | Cancer Sci | 2025 | https://conductscience.org/library/papers/40159464 | PubMed |
| 10 | 39,598,228 | The ncRNA-AURKA Interaction in Hepatocellular Carcinoma: Insights into Oncogenic Pathways, Therapeutic Opportunities, and Future Challenges. | Life (Basel) | 2024 | https://conductscience.org/library/papers/39598228 | PubMed |
1 to 10 of 49
See all 49 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AURKA | 6,790 | PubTator's text mining | https://conductscience.org/library/genes/6790 | NCBI Gene |
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| CCND1 | 595 | PubTator's text mining | https://conductscience.org/library/genes/595 | NCBI Gene |
| STAT3 | 6,774 | PubTator's text mining | https://conductscience.org/library/genes/6774 | NCBI Gene |
| VEGFA | 7,422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41616005
GET https://conductscience.org/api/papers/v1/41616005/references?page=2